These forecasts set a high bar. Companies will need to sustain profitability, while AI adoption should create greater earnings dispersion as businesses vary in their ability to generate revenues, productivity gains, and higher margins.
Market concentration increases the impact of disappointment. The 10 largest companies represent around 40% of the S&P 500, giving revisions to a small group of earnings forecasts an unusually large effect on index returns.
We have moved global equities to Neutral. We still expect markets to rise, with end-2027 price targets of 8,200 for the S&P 500, 7,000 for the Euro Stoxx 50, 1,170 for MSCI Asia ex-Japan, and 1,460 for MSCI AC World.
Prefer the Eurozone
The Eurozone is our preferred regional equity market. We forecast 15% earnings growth in 2027, matching the US, from a lower starting valuation and with less dependence on a few concentrated AI-linked companies.
Listed European companies earn substantial revenues globally, while recovering manufacturing and investment in defense, infrastructure, automation, and electrification should support profits. Healthier banks, relatively low private sector debt, and a broader mix of earnings drivers add to the region’s appeal. To benefit from these dynamics, investors can also consider our “European leaders” stock list.
Moved the US to Neutral
We have moved US equities to Neutral after a period of exceptional earnings growth and a strong market advance. Although we forecast a further earnings increase in 2027, markets are increasingly focusing on whether the current investment cycle can support profits into 2028.
Cannibalization, financing, and execution risks around AI have increased while expectations and index concentration remain high. The market is therefore more sensitive to earnings disappointment or a further rise in discount rates.
While we expect gains, the path could be volatile. Investors should retain their strategic US exposure but use market strength to reduce excess concentration.
Moved Asia ex-Japan and emerging markets to Neutral
We have also moved Asia ex-Japan and emerging market equities to Neutral. Despite high earnings, their opportunity sets are heavily weighted toward semiconductors, memory, and technology hardware, leaving earnings and valuations more exposed to the AI capital-spending cycle.
Within the region, we favor financials in China, Japan, and Singapore for income, rate normalization, and balance sheet strength; China health care for structural innovation and less AI-dependent growth; and domestic-demand beneficiaries in India, Japan, and Singapore.
Diversify sector exposure: Industrials and health care
We favor industrials and health care as two ways to broaden earnings exposure beyond technology.
Investment in automation, defense, transport infrastructure, power networks, and electrification should support industrial earnings. We prefer companies that serve several end markets and have established positions and visible orders over businesses heavily dependent on data center construction.
Health care offers medical innovation and long-term demand. New therapies, obesity treatments, diagnostics, and medical technology should support revenues, while earnings are less tied to corporate investment.
Investors with concentrated US megacap exposure can also diversify with equal-weight strategies, reducing the influence of the largest companies.